Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
J Cutan Pathol ; 50(10): 873-877, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37519087

ABSTRACT

The 2022-2023 mpox outbreak is a global worldwide concern, especially since the virus was previously mainly localized regionally in Central and West Africa. The infection is typically self-limiting and transmitted by close contact/exposure with infected material. Recent cases have been known to present atypically without prodromal symptoms and initially with skin lesions. The histopathology of mpox lesions is rarely reported. Here, we present two middle-aged males presenting initially with painless skin lesions confirmed for mpox by nucleic acid amplification assay. Skin biopsies of the lesion were available for clinicopathologic correlation. Histopathology demonstrated ulceration with viral cytopathologic changes.


Subject(s)
Mpox (monkeypox) , Male , Middle Aged , Humans , Biopsy , Cytology
2.
J Drugs Dermatol ; 11(7): 872-5, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22777233

ABSTRACT

Lichen striatus (LS) is an uncommon linear dermatosis that is primarily seen in children from 4 months to 15 years of age. While some of these eruptions are asymptomatic, others can be quite pruritic. In darker-skinned individuals, post-inflammatory hypopigmentation can be significant and may provide a cause for concern for the patients and/or their parents. In our case series of 4 patients, we observed rapid resolution of LS by combining a topical retinoid with a topical steroid. To our knowledge, this is the first report of successful treatment with this kind of combination therapy in the English literature. The patients not only achieved satisfying cosmesis, but also complete resolution of their pruritus. The most common side effect of topical tazarotene is localized irritation at treatment sites, but the patients in this particular series tolerated the treatment well.


Subject(s)
Dermatologic Agents/therapeutic use , Glucocorticoids/therapeutic use , Lichenoid Eruptions/drug therapy , Retinoids/therapeutic use , Administration, Cutaneous , Child , Child, Preschool , Dermatologic Agents/administration & dosage , Dermatologic Agents/adverse effects , Drug Therapy, Combination , Female , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Humans , Infant , Lichenoid Eruptions/pathology , Male , Nicotinic Acids/administration & dosage , Nicotinic Acids/adverse effects , Nicotinic Acids/therapeutic use , Pruritus/drug therapy , Pruritus/etiology , Retinoids/administration & dosage , Retinoids/adverse effects , Skin Pigmentation , Treatment Outcome
3.
Clin Cancer Res ; 16(24): 5942-8, 2010 Dec 15.
Article in English | MEDLINE | ID: mdl-21045084

ABSTRACT

Low cancer survival rates and the serious side effects often associated with current chemotherapeutics highlight the need for new and effective nontoxic anticancer agents. Since 1997 when Jang and colleagues first described resveratrol's ability to inhibit carcinogenesis, it has consistently proven effective at tumor inhibition in diverse human cancer models. This finding has raised the hope that resveratrol would pioneer a novel class of nontoxic chemotherapeutics. As a consequence of initial basic and preclinical studies, resveratrol is now being extensively promoted in the unregulated nutraceutical sector. However, some fundamental aspects of resveratrol's action need to be understood before it can be developed into a clinically viable anticancer drug. These areas pertain to the key mechanism(s) by which resveratrol potentiates its antitumor effects. Current research suggests that these mechanisms might be through novel pathways, requiring an understanding of cellular uptake, sentinel targets, and in vivo biological networks. The metabolism of resveratrol and its bioavailability also warrant further consideration in light of recent in vitro and in vivo studies. Finally, we need to appreciate the sorts of information about resveratrol that may translate between different disease entities. We present a critical discussion of these issues and suggest important experiments that could pave the way to the successful translation of resveratrol to the clinic.


Subject(s)
Stilbenes/pharmacology , Stilbenes/therapeutic use , Translational Research, Biomedical , Animals , Antineoplastic Agents/adverse effects , Antineoplastic Agents/pharmacokinetics , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Clinical Trials as Topic , Dietary Supplements , Drug Delivery Systems , Evaluation Studies as Topic , Humans , Models, Biological , Resveratrol , Stilbenes/adverse effects , Stilbenes/pharmacokinetics , Translational Research, Biomedical/methods , Translational Research, Biomedical/standards
5.
Cutis ; 84(1): 22-6, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19743721

ABSTRACT

We report an unusual case of minocycline-induced pigmentation mimicking persistent ecchymosis in a patient with persistent (20 months' duration) bluish black discoloration of the medial and lateral aspects of the left ankle following an avulsion fracture. We review the common presentations of minocycline-induced pigmentation as well as some of the more unusual presentations.


Subject(s)
Anti-Bacterial Agents/adverse effects , Minocycline/adverse effects , Pigmentation Disorders/chemically induced , Ankle/pathology , Ankle Injuries/rehabilitation , Ecchymosis/diagnosis , Female , Fractures, Bone/rehabilitation , Humans , Pigmentation Disorders/diagnosis , Time Factors , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...